Live Feeds
● TRACKER Updated 14d ago · 7 sources tracked

Lilly snags another Massachusetts biotech as local headcount surges past 1,400

Eli Lilly has acquired Merida Biosciences for up to $2.875 billion, expanding its autoimmune and allergic disease treatment offerings. The deal adds to Lilly's growing presence in Massachusetts, where its headcount has surged past 1,400. Merida's treatments target rogue antibodies. Lilly aims to advance its immune drug pipeline with this acquisition.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Eli Lilly acquired Merida Biosciences for $2.88 billion.
  • ✓ The acquisition targets treatments for autoimmune and allergic diseases.
  • ✓ Eli Lilly's headcount in Massachusetts has surged past 1,400.
🛡️ Source Corroboration: 7 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly announced its acquisition of Merida Biosciences, further expanding its presence in Massachusetts.

Live updates

  1. Eli Lilly acquires Merida Biosciences for $2.88B

    Eli Lilly has acquired Merida Biosciences for up to $2.875 billion, expanding its autoimmune and allergic disease treatment offerings. The deal adds to Lilly's growing presence in Massachusetts, where its headcount has surged past 1,400. Merida's treatments target rogue antibodies. Lilly aims to advance its immune drug pipeline with this acquisition.

    Why it matters

    This acquisition is part of Eli Lilly's strategy to bolster its portfolio of autoimmune and allergic disease treatments. The deal reflects Lilly's growing investment in the Massachusetts biotech sector. The acquisition will contribute to Lilly's pipeline of treatments for serious autoimmune and allergic diseases.

    What is confirmed

    • Eli Lilly acquired Merida Biosciences for $2.88 billion.
    • The acquisition targets treatments for autoimmune and allergic diseases.
    • Eli Lilly's headcount in Massachusetts has surged past 1,400.

    What to watch next

    • Lilly's integration of Merida Biosciences
    • Future acquisitions in the Massachusetts biotech sector
    • Regulatory review of the acquisition
    Sources used for this update (7)
    1. Fierce Biotech — Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
    2. WSJ — Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
    3. Bloomberg.com — Lilly to Buy Merida for $2.88 Billion in Autoimmune Push
    4. BioPharma Dive — Lilly adds to immune drug pipeline with $2.9B Merida buyout
    5. bizjournals.com — Lilly snags another Massachusetts biotech as local headcount surges past 1,400
    6. Yahoo Finance — SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
    7. PR Newswire — Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community